Response assessment in acute myeloid leukemia by flow cytometry supersedes cytomorphology at time of aplasia, amends cases without molecular residual disease marker and serves as an independent prognostic marker at time of aplasia and post-induction

Thomas Köhnke; Veit Bücklein; Sandra Rechkemmer; Stephanie Schneider; Maja Rothenberg-Thurley; Klaus H Metzeler; Maria-Cristina Sauerland; Wolfgang Hiddemann; Karsten Spiekermann; Marion Subklewe

doi:10.3324/haematol.2018.215236

Response assessment in acute myeloid leukemia by flow cytometry supersedes cytomorphology at time of aplasia, amends cases without molecular residual disease marker and serves as an independent prognostic marker at time of aplasia and post-induction

Haematologica. 2019 Nov;104(11):e510-e513. doi: 10.3324/haematol.2018.215236. Epub 2019 Apr 4.

Authors

Thomas Köhnke^{1

2}, Veit Bücklein^{1

2}, Sandra Rechkemmer¹, Stephanie Schneider^{1

3}, Maja Rothenberg-Thurley^{1

4

5}, Klaus H Metzeler^{1

4

5}, Maria-Cristina Sauerland⁶, Wolfgang Hiddemann^{1

4

5}, Karsten Spiekermann^{1

4

5}, Marion Subklewe^{7

2

4

5}

Affiliations

¹ Laboratory for Leukemia Diagnostics, Department of Medicine III, University Hospital, LMU Munich, Munich.
² Translational Cancer Immunology, Gene Center, LMU Munich, Munich.
³ Institute of Human Genetics, LMU Munich, Munich.
⁴ German Cancer Consortium (DKTK), Heidelberg.
⁵ German Cancer Research Center (DKFZ), Heidelberg.
⁶ Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany.
⁷ Laboratory for Leukemia Diagnostics, Department of Medicine III, University Hospital, LMU Munich, Munich marion.subklewe@med.uni-muenchen.de.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Biomarkers
Bone Marrow / pathology*
Female
Flow Cytometry
Humans
Immunophenotyping
Leukemia, Myeloid, Acute / complications
Leukemia, Myeloid, Acute / diagnosis*
Leukemia, Myeloid, Acute / etiology
Leukemia, Myeloid, Acute / therapy
Male
Middle Aged
Neoplasm, Residual / diagnosis*
Prognosis
Remission Induction
Survival Analysis

Substances

Biomarkers